The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time […]
Biomedical Business Continuity: Build Resilience or Lose Market Share Read Post »
Own the Market After Your Patent Dies A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and
How to own a Market you Don’t Own: Market Access Strategies Post-Drug Patent Expiration Read Post »
Why Formulation Patents Are the Most Undervalued Asset in Pharma IP The pharmaceutical industry spent roughly $260 billion on R&D
For biopharma IP teams, portfolio managers, R&D leads, and institutional investors who track biologic patent cliffs for a living. 1.
Biosimilar Patent Strategy: The Complete IP, Litigation, and Market Entry Playbook Read Post »
Books and Research Papers Citing DrugPatentWatch All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 2025 — 11 Books and Research Papers Citing DrugPatentWatch Gregory, A. (2025).
How Academic Researchers and Policy Experts Use DrugPatentWatch Read Post »
A playbook for IP teams, portfolio managers, and R&D leads — from Paragraph IV mechanics and biosimilar patent dance tactics
The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated
How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what
The patent system did not anticipate generative chemistry. When Congress codified the requirement that inventors be ‘natural persons’ in 35
Who Owns the AI-Discovered Drug? The Patent Ownership Guide Pharma IP Teams Need Now Read Post »
Sign in or create a free account to read this DrugPatentWatch article
